Genenta shares rose 10% premarket after reporting encouraging long-term survival data from its Temferon cell-therapy study in newly diagnosed glioblastoma patients. Of 25 treated patients, 44% reached 18-month survival, and median overall survival remained 17 months. One patient has survived three years, offering rare durability against this highly aggressive tumor.